ReviewMedicines (Basel, Switzerland)2018
New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.
Review in Medicines (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis.American journal of men's healthPooled it
- Frequency of cannabis use and symptoms of anxiety and depression: a cross-sectional analysis of the Colorado cannabis users health cohort.Journal of cannabis research · 2025Article
- Public health unit engagement in school mental health programs and adolescent mental health during the COVID-19 pandemic: COMPASS, 2018-2022.Journal of public health (Oxford, England) · 2024Article
- Characterizing Cannabis Use and Perceived Benefit in a Tertiary Headache Center Patient Sample.Neurology. Clinical practice · 2024Article
- Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19-A Scoping Review.Journal of clinical medicine · 2023Article
- Magnitude of Substance Use and Its Associated Factors Among the Medical Students in India and Implications for Medical Education: A Narrative Review.Indian journal of psychological medicine · 2022Article
- Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents.Current neuropharmacology · 2022Review
- Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder.IBRO neuroscience reports · 2021Review
- Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion.Journal of cannabis research · 2021Article
- Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases.Current neuropharmacology · 2021Review
- A bio-inspired cell-free system for cannabinoid production from inexpensive inputs.Nature chemical biology · 2020Article
- A novel bioassay for quantification of surface Cannabinoid receptor 1 expression.Scientific reports · 2020Article
- Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression.Biomolecules · 2020Article
- Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.Cannabis and cannabinoid research · 2020Review
- Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors.Frontiers in pharmacology · 2020Article
- Cannabinoid Regulation of Fear and Anxiety: an Update.Current psychiatry reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Following the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cannabidiol are the most abundant phytocannabinoids found in cannabis extracts, as well as the most studied. The present review aims to provide an overview of the current evidence for their beneficial effects in treating psychiatric disorders, including schizophrenia, anxiety, and depression. Nevertheless, further investigations are required to clarify many pending issues, especially those relative to the assessment of benefits and risks when using cannabis for therapeutic purposes, thereby also helping national and federal jurisdictions to remain updated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.